Vera Therapeutics, Inc.
VERA
$36.70
$0.090.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 123.42M | 100.22M | 80.89M | 62.92M | 49.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 383.41M | 315.47M | 270.18M | 236.05M | 193.25M |
| Operating Income | -383.41M | -315.47M | -270.18M | -236.05M | -193.25M |
| Income Before Tax | -368.95M | -299.61M | -251.94M | -218.28M | -175.46M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -368.95 | -299.62 | -251.94 | -218.28 | -175.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -368.95M | -299.62M | -251.94M | -218.28M | -175.46M |
| EBIT | -383.41M | -315.47M | -270.18M | -236.05M | -193.25M |
| EBITDA | -382.89M | -315.01M | -269.79M | -235.77M | -193.07M |
| EPS Basic | -5.54 | -4.66 | -3.98 | -3.58 | -2.99 |
| Normalized Basic EPS | -3.46 | -2.91 | -2.49 | -2.24 | -1.87 |
| EPS Diluted | -5.54 | -4.66 | -3.98 | -3.58 | -2.99 |
| Normalized Diluted EPS | -3.46 | -2.91 | -2.49 | -2.24 | -1.87 |
| Average Basic Shares Outstanding | 264.74M | 256.93M | 252.00M | 243.05M | 233.99M |
| Average Diluted Shares Outstanding | 264.74M | 256.93M | 252.00M | 243.05M | 233.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |